

Cover Story
Free
The FDA Oncologic Drugs Advisory Committee March 7 voted to accept the metric of “minimal residual disease,” or MRD, as a basis for approval of a drug for the treatment of acute lymphoblastic leukemia.
In Brief
Funding Opportunities
Trending Stories
- Anthony G. Letai to be named NCI director
The Dana-Farber and Harvard physician-scientist is an inspired choice, colleagues say - NCI releases names of members of ad hoc working group—filling the void left by BSA
- Trump’s FDA invents an unusual regulatory pathway to approve leucovorin for autism
Experts call the move “extremely premature” - ACOG says it will no longer accept federal funding
- Bhattacharya: New grant review criterion is “not political”
- Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer